Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

CRESIB coordinates an international consortium to fight malaria caused by Plasmodium vivax

18.07.2007
The CRESIB has today presented the research programme on malaria by Plasmodium vivax, a parasite causing over 70 million yearly cases of malaria in the world. This new programme will be developed in coordination with the leading international centres and researchers on P.vivax.

The aim of this study is to contribute to a better understanding of malaria by P. vivax and to support and accelerate the development of new control tools, with a special focus in vaccines. This fact will promote the creation and development of a research line on P. vivax in CRESIB under the direction of Dr. Hernando A. del Portillo, one of the few specialists in molecular biology and vaccine development against this parasite. The number of CRESIB labs will be increased, with an enlargement and restoration of current facilities to meet the needs of the centre.

Malaria is an infectious disease which can be caused by four species of the Plasmodium parasite: P. falciparum, P. vivax, P. malariae and P. ovale. P. falciparum and P. vivax are the most prevalent, the first being more virulent and responsible of most of the severe morbidity and mortality. Nevertheless, during the last years, there has been a growing interest in malaria by P. vivax, which, as well as causing millions of malaria cases every year, it also generates a high social and economic cost for endemic countries. It is estimated that about 2,600 million people live in risk zones for P. vivax: central and south-America, Asia, Middle East and occidental Pacific. Clinical and pathogen presentation of P. vivax is not well understood. Despite the traditional belief that clinical malaria caused by this species of the parasite is mild, there are evidences suggesting that it can cause severe clinical patterns and even death of patients.

The paradox is that even though malaria by P. vivax has large global disease burden, this is a poorly studied disease, which has been long forgotten. Consequently, this new research programme has a large importance, and an estimated initial duration of 4 years.

This is the reason why CRESIB, through DR. Hernando A. del Portillo, specialist in molecular biology and vaccine development against Plasmodium vivax, gives plenty of importance to the development of new control tools for this type of malaria.

In the field of malaria by P. vivax, there has been until now a lack of initiatives to promote the global effort in the research on this disease. With the experience of the CRESIB group in malaria and of the Clínic Foundation for Biomedical Research (FCRB, Fundació Clínic per a la Recerca Biomèdica) in the management and coordination of projects of international research, an international consortium of research in P. vivax will be created and promoted. This consortium will be constituted by leading malaria research centres, and will be coordinated from Barcelona.

Research centres collaborating in this project, mostly placed in malaria endemic areas by Plasmodium vivax, are: Papua New Guinea Institute of Medical Research, located in Papua New Guinea; the International Centre for Genetic Engineering and Biotechnology, located in New Delhi (India), the Tropical Medicine Foundation of Amazonas, in Manaus (Brazil) and the International Vaccine Centre, located in Cali (Colombia).

About CRESIB:
Research on poverty-related diseases is one of our main tools to try to break the vicious circle between disease and poverty and to have an impact on the development of low-income countries. It is in this sense that the CRESIB has been created in Catalonia, an institute born from the scientific support of the International Health Centre of Hospital Clínic and founded by the Catalan Government through the Department of Health and the Department of Innovation, Universities and Enterprises; the Universitat de Barcelona(UB); the Hospital Clínic de Barcelona; and the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) with the objective to conduct excellence research in international health and to contribute to the global effort in the fight against poverty-related diseases.

CRESIB has a scientific programme including research on diseases causing an important part of the morbidity and mortality in low-income countries, specially malaria, acute respiratory infections, diarrhoeas, tuberculosis and AIDS. Furthermore, CRESIB sets its sights on promoting research related to other aspects of international health, such as emergent, reemergent and immunopreventable diseases, health, immigration and climate and health. Research conducted by CRESIB researchers is currently developed in the facilities located in the Campus of the Faculty of Medicine of the Universitat de Barcelona-Hospital Clínic.

Department of Communication and External Relations of the IDIBAPS - Hospital Clínic of Barcelona

For further information, please contact us at +34 93 227 57 00
Marc de Semir/Gemma Moya

Marc de Semir | EurekAlert!
Further information:
http://www.cresib.cat
http://www.ub.es

More articles from Health and Medicine:

nachricht Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care

nachricht Disrupted fat breakdown in the brain makes mice dumb
19.05.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

Im Focus: Using graphene to create quantum bits

In the race to produce a quantum computer, a number of projects are seeking a way to create quantum bits -- or qubits -- that are stable, meaning they are not much affected by changes in their environment. This normally needs highly nonlinear non-dissipative elements capable of functioning at very low temperatures.

In pursuit of this goal, researchers at EPFL's Laboratory of Photonics and Quantum Measurements LPQM (STI/SB), have investigated a nonlinear graphene-based...

Im Focus: Bacteria harness the lotus effect to protect themselves

Biofilms: Researchers find the causes of water-repelling properties

Dental plaque and the viscous brown slime in drainpipes are two familiar examples of bacterial biofilms. Removing such bacterial depositions from surfaces is...

Im Focus: Hydrogen Bonds Directly Detected for the First Time

For the first time, scientists have succeeded in studying the strength of hydrogen bonds in a single molecule using an atomic force microscope. Researchers from the University of Basel’s Swiss Nanoscience Institute network have reported the results in the journal Science Advances.

Hydrogen is the most common element in the universe and is an integral part of almost all organic compounds. Molecules and sections of macromolecules are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

Innovation 4.0: Shaping a humane fourth industrial revolution

17.05.2017 | Event News

Media accreditation opens for historic year at European Health Forum Gastein

16.05.2017 | Event News

 
Latest News

New approach to revolutionize the production of molecular hydrogen

22.05.2017 | Materials Sciences

Scientists enlist engineered protein to battle the MERS virus

22.05.2017 | Life Sciences

Experts explain origins of topographic relief on Earth, Mars and Titan

22.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>